Innovations at INTERPHEX Guide 2022 - 23

for emerging companies who are more focused on the science
of their molecule rather than its manufacturing. This serves as an
additional challenge atop of shortened timelines and highlights
the importance of working with a strategic partner.
How has the COVID-19 pandemic affected
the production of APIs in general and
HPAPIs specifically?
The pandemic continues to be a global challenge, but it has
pushed us to innovate and improve the way we manage our
supply chain. Our global network of sites has allowed us to
manage supply and demand to the best degree possible.
We continuously work to rapidly build and expand our
manufacturing capabilities and supply chains to ensure our
partners receive uninterrupted support.
Specifically, transporting select bulky chemicals overseas is
impacted by fluctuations in travel and shipment regulations
due to the crisis. One solution is to have a global supply
network that has access to local and regional resources. With
our expanded labs at our Nansha, China site, we have access to
China's rich biopharma ecosystem which allows us to leverage
world-class, high-quality and reliable local suppliers of raw
materials to help further increase the speed of problem-solving
and manufacturing.
Looking forward, how will Lonza continue to
be an important partner for its current and
future clients specifically in regards API and
HPAPI development and production?
Lonza is committed to working as one with our partners from
early- to late-stage development and commercial manufacturing.
We work to support small and emerging companies who bring a
majority of these innovative HPAPIs in the pipeline and provide
them with manufacturing expertise and world-class facilities. Our
recent expansion of our labs with HPAPI capabilities in Nansha,
China builds on our early-phase capabilities - a critical stage for
HPAPI products that will position them for a successful scale up
in our global network.
We see a strong interest in our Nansha capabilities from
European and US headquartered customers. As an example, we
recently announced our collaboration with Swedish company
Oasmia Pharmaceutical AB to deliver cGMP-standard drug
substance for their ovarian cancer drug candidate Cantrixil at
our Nansha site. To support them through the planned Phase
II clinical trials, Lonza will provide Oasmia Pharmaceutical AB
kilogram-scale synthesis, purification, and stability testing
of the Cantrixil, and deliver cGMP batches of drug substance
through the trials.
www.americanpharmaceuticalreview.com |
| 23
http://www.americanpharmaceuticalreview.com
Innovations at INTERPHEX Guide 2022

Table of Contents for the Digital Edition of Innovations at INTERPHEX Guide 2022
